Evidence map›Paper›PMID 30076163›Full record

ArticleBMJ case reports2018

Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement.

Gulcin Elboga, Zeynel Abidin Sayiner

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Testosterone and Suicidal Behavior in Bipolar Disorder.International journal of environmental research and public health · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Gulcin ElbogaDepartment of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.ORCID http://orcid.org/0000-0003-3903-1835
Zeynel Abidin SayinerDepartment of Endocrinology and Metabolism, School of Medicine, Gaziantep University, Gaziantep, Turkey.ORCID http://orcid.org/0000-0001-5105-0292
Gaziantep University · TRSchreiner Group (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypogonadotropic hypogonadism is a rare congenital disorder characterised by the deficiency and the absence of puberty and infertility. It is caused by the deficient production, secretion or action of gonadotropin-releasing hormone, which is the master hormone regulating the reproductive axis. Gonadotropin-releasing hormone or gonadotropin injections and testosterone replacement therapy are required in the treatment of this disorder. Psychiatric symptoms and disorders may be seen with the use of anabolic androgenic steroids. In this case report, we present a case report in which a patient had behavioural symptoms in childhood and develops bipolar disorder after testosterone replacement therapy. This patient was reached to the remission by increasing the doses of psychiatric drugs without interfering with hormonal therapy. It should be considered that patients receiving testosterone replacement therapy may develop bipolar disorder or trigger mood changes in bipolar mood disease, so behavioural and mood state changes should be closely followed in patients who have bipolar mood disease.

Indexed as

AdultAntimanic AgentsAntipsychotic AgentsBipolar DisorderChorionic GonadotropinHormone Replacement TherapyHumansHypogonadismMaleRisperidoneTestosteroneValproic AcidAntimanic AgentsAntipsychotic AgentsChorionic GonadotropinRisperidoneTestosteroneValproic Acidbipolar I iisorderpsychiatry (drugs and medicines)unwanted effects / adverse reactions

Identifiers

PMID30076163
PMCPMC6078280
OpenAlexW2886600370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.